The estimated Net Worth of John Leite is at least $2.5 Milione dollars as of 4 September 2024. John Leite owns over 5,479 units of Veracyte Inc stock worth over $2,309,596 and over the last few years John sold VCYT stock worth over $195,090.
John has made over 2 trades of the Veracyte Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently John sold 5,479 units of VCYT stock worth $163,165 on 4 September 2024.
The largest trade John's ever made was selling 5,479 units of Veracyte Inc stock on 4 September 2024 worth over $163,165. On average, John trades about 845 units every 6 days since 2023. As of 4 September 2024 John still owns at least 76,174 units of Veracyte Inc stock.
You can see the complete history of John Leite stock trades at the bottom of the page.
John's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, , SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo e Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: